USFDA gives tentative nod to Glenmark for Calcipotriene and Betamethasone Dipropionate foam

Calcipotriene and Betamethasone Dipropionate foam approved

74
USFDA
Picture: Pixabay

Last Updated on May 10, 2022 by The Health Master

Glenmark Pharma has been granted tentative approval by the US Food and Drug Administration (USFDA) for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%, the generic version of Enstilar Foam, 0.005%|0.064%, of Leo Pharma AS.

According to IQVIA sales data for the 12-month period ending March 2022, the Enstilar Foam 0.005% |0.064% market achieved annual sales of approximately $115.2 million.

USFDA gives tentative approval for this Hypertension drug

USFDA gives tentative nod to Zydus for Selexipag tablets

USFDA gives approval to Lupin Pregabalin capsules

USFDA gives final approval to Aleor Dermaceuticals for Docosanol cream

USFDA gives nod to these companies for Bortezomib for injection

USFDA grants approval for drug to treat spondylitis

FAQs – on Blood Bags and its Testing

USFDA gives tentative approval for this Hypertension drug

Man held in Internet pharmacy racket, Rs 3.17 cr cash seized

Man gets 10-years rigorous imprisonment for making drugs illegally

USFDA gives tentative nod to Zydus for Selexipag tablets

Govt releases guidelines on Pharma innovation and entrepreneurship for academic institutions

USFDA gives approval to Lupin Pregabalin capsules

Global drug development centre set up for APIs and Formulations

New molecule discovered that can be used for treatment of diabetes

Latest Notifications regarding Pharmaceuticals